Abstract |
Thirty cases of plasma cell neoplasms (24 multiple myeloma, one plasma cell leukemia, and three primary macroglobulinemia) were treated with two kinds of highly purified alpha- interferons, recombinant human leukocyte interferon (rIFN-alpha A) (16 cases) and human lymphoblastoid interferon (HLBI) (14 cases). Partial remission (PR) was obtained in two of 16 evaluable cases treated with rIFN-alpha A and in two of 12 evaluable cases treated with HLBI. If minor response (MR) was included, responses were observed in seven (31.3%) and six (50%), respectively. Response (PR + MR) was noted in 38% of 21 previously treated patients and 71% of seven previously untreated patients. Side-effects were noted in more than two-thirds of the patients. They included fever, malaise, nausea/ anorexia and myelosuppression. Thus, these two kinds of highly purified alpha-interferon were effective in plasma cell neoplasm, producing unequivocal response in 14.3% of the cases without unacceptable side-effects.
|
Authors | R Ohno, Y Kodera, M Ogura, T Murase, N Emi, M Okumura, Y Morishita, E Nagura, S Minami, Y Morishima |
Journal | Cancer chemotherapy and pharmacology
(Cancer Chemother Pharmacol)
Vol. 14
Issue 1
Pg. 34-7
( 1985)
ISSN: 0344-5704 [Print] Germany |
PMID | 3917376
(Publication Type: Journal Article)
|
Chemical References |
- DNA, Recombinant
- Interferon Type I
|
Topics |
- Aged
- DNA, Recombinant
- Dose-Response Relationship, Drug
- Drug Evaluation
- Female
- Humans
- Interferon Type I
(adverse effects, therapeutic use)
- Leukemia, Plasma Cell
(therapy)
- Male
- Middle Aged
- Multiple Myeloma
(therapy)
- Waldenstrom Macroglobulinemia
(therapy)
|